Cisplatin is one of the most commonly used chemotherapeutic agents, with demonstrated activity against a diverse spectrum of malignancies, including testicular cancer, ovarian carcinoma, and head/neck tumors. However, the therapeutic efficacy of the drug is limited by the severity of its side effects and the potential progression of tumor cells to a cisplatin-resistant state. We found that the transcription factors of genes involved in cisplatin resistance are often overexpressed or activated in cisplatin-resistant cells. In this paper, we describe ATF4, Clock, ZNF143, and YB-1 as cisplatin resistance genes. Clock and the ATF4 transcription system might play an important role in multidrug resistance through the glutathione-dependent redox system, and the physiological potential of the Clock-controlled redox system might be important to better understand oxidative stress-associated disorders including cancer and systemic chronotherapy. We also describe the basis for understanding the effects of cisplatin on mitochondrial activity and the mechanisms of cellular toxicity and resistance caused by this drug.
|Number of pages||9|
|Journal||Rinsho byori. The Japanese journal of clinical pathology|
|Publication status||Published - Oct 2009|
All Science Journal Classification (ASJC) codes